NICE appraisal outcome - have your say!

Due to the recent draft guidance released by NICE which sees both Efgartigimod and Ravulizumab receive initial negative recommendations, we would like to gauge the impact of this decision on the myasthenia gravis community. Any information you provide will be shared with NICE as part of the public consultation that is taking place on both treatments. It is important to remember that the majority of treatments appraised by NICE receive a negative recommendation at this stage, and many then go on to be recommended for NHS use.

You can view the NICE draft guide on Efgartigimod here and on Ravulizumab here.

The survey should take no longer than five minutes to complete, and we greatly appreciate you taking the time to submit. This survey is intended for anyone with myasthenia gravis.

This survey will close for responses on Sunday the 15th of October.